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Summary
Objectives: To determine the proportion of responders in two identical osteoarthritis (OA) trials using Outcome Measures in Arthritis Clinical
TrialseOsteoarthritis Research Society International (OMERACTeOARSI) criteria and to assess the comparability and correlation of individ-
ual component measurements.
Methods: Data were pooled from two identical 26-week, double-blind, randomized, parallel, multicenter trials comparing once daily etoricoxib
30 mg (N¼ 475), celecoxib 200 mg (N¼ 488), and placebo (N¼ 244) in patients with OA of the knee or hip. OMERACTeOARSI criteria were
(1) improvement in pain or physical function 50% and an absolute change 20 mm on a 100-mm visual analog scale (VAS); or (2) improve-
ment of 20% and with an absolute change 10 mm in at least two of the following three categories: pain, physical function, and patient’s
global assessment. Correlations were assessed between endpoints measured as time-weighted average change from baseline over 12
weeks using Pearson’s correlation coefﬁcient (r).
Results: There were signiﬁcantly greater proportions of responders in the etoricoxib (66.2%) and celecoxib (63.5%) groups compared with the
placebo group (43.0%; P< 0.001). There was no difference between the two active treatment groups. There was high correlation between
pain and physical function (r¼ 0.903), pain and global assessment (r¼ 0.778), and physical function and global assessment (r¼ 0.820). There
was high sensitivity (75e87%) and speciﬁcity (80e96%) for changes in individual component measurements to predict OMERACTeOARSI
responders.
Conclusions: Signiﬁcantly more patients receiving etoricoxib or celecoxib than placebo were OMERACTeOARSI responders. The high
correlation between individual scales composing this composite response measurement suggests some redundancies between individual
components, particularly between pain and physical function.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Both the Osteoarthritis Research Society International
(OARSI)1 and the Outcome Measures in Arthritis Clinical
Trials (OMERACT)2 groups have recommended that trials
evaluating therapies targeting symptomatic relief in osteoar-
thritis (OA) include a core set of measurements assessing
pain, physical function, patient’s global assessment, and,
in studies of greater than 1-year duration, also include joint
imaging. Although a common set of measurements would
make it easier to assess results from multiple trials, the
use of various and disparate outcome measurement instru-
ments, such as the Western Ontario McMaster Universities
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1289Measurement Scales (AIMS)4, and Lequesne OA Index5,
hinders the ability to reliably compare outcomes across
studies.
As such, the OMERACTeOARSI developed a set of
standardized criteria to identify responders and nonre-
sponders in OA of the knee or hip6,7, similar to the compos-
ite American College of Rheumatology response criteria
developed for rheumatoid arthritis8 and to the Assessment
in Ankylosing Spondylitis criteria more recently established
for ankylosing spondylitis9. The OMERACTeOARSI
responder index has been validated in 14 trials and was
developed to distinguish between an efﬁcacious active
treatment and placebo. The OMERACTeOARSI criteria
for response are (1) improvement in pain or physical func-
tion 50% and an absolute change 20 mm; or (2)
improvement of 20% with an absolute change 10 mm
in at least two of the following three categories: pain,
physical function, and patient’s global assessment7.
In this secondary analysis of data pooled from two previ-
ously published studies of identical design10, we sought to
1290 C. O. Bingham et al.: OMERACTeOARSI responder analysisdetermine treatment response using the OMERACTe
OARSI criteria in patients receiving etoricoxib 30 mg, cele-
coxib 200 mg, or placebo once daily for 12 weeks. In
addition, we assessed the ability of the individual components
of the criteria (i.e., pain, physical function, and patient’s global
assessment) to predict overall OMERACTeOARSI response,
as well as the correlation between those components.Patients and methodsSTUDY DESIGN AND POPULATIONDetails of the original studies have been previously published10.
Clinical efﬁcacy and safety data were collected at 2, 4, 8, 12, 16, and 26
weeks. The three co-primary efﬁcacy endpoints were the changes from
baseline over 12 weeks in WOMAC pain subscale, WOMAC physical func-
tion subscale, and patient’s global assessment of disease status (PGADS),
each measured on a 100-mm visual analog scale (VAS).STATISTICAL ANALYSESTable I
Summary of patient characteristics, pooled population
Etoricoxib 30 mg
(N¼ 475)
Celecoxib 200 mg
(N¼ 488)
Placebo
(N¼ 244)
Sex, n (%)
Female 323 (68.0) 321 (65.8) 159 (65.2)
Age, mean
years (SD)
62.0 (9.9) 62.4 (9.4) 61.9 (9.2)
Race, n (%)
Asian 4 (0.8) 3 (0.6) 2 (0.8)
Black 33 (6.9) 40 (8.2) 22 (9.0)
Hispanic 13 (2.7) 15 (3.1) 8 (3.3)
White 423 (89.1) 427 (87.5) 209 (85.7)
Other 2 (0.4) 3 (0.6) 3 (1.2)
Primary study joint, n (%)
Knee 367 (77.3) 385 (78.9) 202 (82.8)
Hip 108 (22.7) 103 (21.1) 42 (17.2)
Prior medicine use, n (%)
Acetaminophen 58 (12.2) 80 (16.4) 40 (16.4)As with the primary analyis10, the present analysis was a modiﬁed inten-
tion-to-treat approach on the time-weighted average response; all patients
with a baseline efﬁcacy measurement and at least one post-baseline obser-
vation were included. Only observed data were included in the time-weighted
average response; no data were carried forward or imputed for this compu-
tation. The three primary efﬁcacy variables were assessed by an analysis of
covariance (ANCOVA) model with factors for treatment group, primary OA
joint, and baseline (ﬂare) score. The present analysis was based on the
change from baseline over 12 weeks in the three co-primary efﬁcacy end-
points, and was based on data pooled from the both primary studies.
Because of the identical and concurrent nature of the two separate trials,
we pooled the data to provide a more robust data set from which to perform
these post-hoc analyses. In addition, because of the generally similar base-
line characteristics and efﬁcacy results reported in the primary report10, we
felt that the pooled patient group was representative of the individual treat-
ment groups and would not be subject to a confounding cohort effect.
Because we found no difference in efﬁcacy by primary study joint in the
main study report, and because only approximately 20% of patients identiﬁed
hip as the primary OA joint10, we also pooled patients together irrespective of
primary study joint. Responders were identiﬁed according to OMERAC-
TeOARSI criteria7, deﬁned as (1) improvement in pain or physical function
50% and an absolute change 20 mm; or (2) improvement of 20% with
an absolute change 10 mm in at least two of the following three: pain, phys-
ical function, and patient’s global assessment. We also calculated the per-
centage of responders as a function of WOMAC pain, WOMAC physical
function, and PGADS response tertile to evaluate the ability and similarity
of each measurement in identifying responders and nonresponders. This
analysis was based on a previous study of low back pain showing that the
cutpoint value between the bottom response tertile and the top two response
tertiles was similar to the minimally clinically important change (MCIC)11 re-
ported in the literature, and thus was an approximation to identify re-
sponders. The cutpoints for changes from baseline in VAS scores
between the top two tertiles and the bottom tertile in the present analysis
were 11.86 mm for WOMAC pain, 8.70 mm for WOMAC physical func-
tion, and 12.86 mm for PGADS. These values were used to calculate the
sensitivity and speciﬁcity of each of the three endpoints in correctly identify-
ing patients as OMERACTeOARSI responders and nonresponders. Correla-
tions between efﬁcacy measurements were assessed using Pearson’s
correlation coefﬁcient (r). We also evaluated mean changes from baseline
in the three outcome measures by quantile. The analysis of treatment means
by tertile was based on an ANCOVA model, which included factors for pro-
tocol, treatment, primary OA joint, baseline covariate, responder status, and
treatment by responder status interaction.
ResultsNSAID/coxib 417 (87.8) 408 (83.6) 204 (83.6)PATIENT ACCOUNTINGLow-dose aspirin
use, n (%)
141 (29.7) 135 (27.7) 79 (32.4)
Baseline (ﬂare) efﬁcacy scores, mean mm (SD)
WOMAC pain 68.0 (16.3) 67.3 (17.5) 66.4 (16.4)
WOMAC
physical function
66.6 (17.7) 66.1 (18.8) 64.9 (18.2)
PGADS 72.7 (17.0) 70.7 (17.8) 70.6 (17.7)In the pooled study population, 1207 patients were
randomly assigned to etoricoxib 30 mg (N¼ 475), celecoxib
200 mg (N¼ 488), or placebo (N¼ 244) once daily for 12
weeks. Overall, patient characteristics were consistent
across treatment groups (Table I). The majority of patients
were white (w88%), women (w66%), and had a mean
age of approximately 62 years. Most (w85%) had been
on a nonsteroidal anti-inﬂammatory drug (NSAID) orcyclo-oxygenase (COX)-2 selective inhibitor prior to enroll-
ment and approximately 29% were taking low-dose aspirin.
As reported in the primary publication, there were signiﬁ-
cantly (P< 0.001) more discontinuations due to lack of efﬁ-
cacy with patients receiving placebo (28.7%) than with
those receiving etoricoxib (6.1%) or celecoxib (9.4%)10. Pa-
tients receiving placebo also used signiﬁcantly (P< 0.001)
more rescue acetaminophen (mean, 1.88 tablets/day)
than those receiving etoricoxib (mean, 1.17 tablets/day) or
celecoxib (mean, 1.23 tablets/day).RESPONDER ANALYSISFor thepooledstudies, theproportionofOMERACTeOARSI
responders was 66.2%, 63.5%, and 43.0% in the
etoricoxib, celecoxib, and placebo groups, respectively.
The response rate was signiﬁcantly greater in the
etoricoxib and celecoxib groups than in the placebo group
(P< 0.001). Similar results were seen in each component
trial; the proportions of responders in Study 1 were 67.5%
for etoricoxib, 65.7% for celecoxib, and 41.6% for
placebo; in Study 2, the proportions were 65.0% for
etoricoxib, 61.4% for celecoxib, and 44.6% for placebo.
The time-weighted average changes from baseline by quan-
tile of response are shown in Fig. 1, including the 67th per-
centile cutpoint for responders in each category. When
using these cutpoints to assess the ability of the individual
measurements to predict response based on tertile group,
there was high sensitivity (75e87%) and speciﬁcity
(80e96%) for each treatment group within each measure-
ment to predict OMERACTeOARSI responders (Table II).
For all treatment groups and measurements combined,
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Fig. 1. Time-weighted average change (mm) from baseline over 12 weeks by response percentile.
1291Osteoarthritis and Cartilage Vol. 16, No. 11there was 85.3% sensitivity and 89.1% speciﬁcity for identi-
fying OMERACTeOARSI responders.CORRELATION OF OUTCOME MEASURESAs shown in Table III, time-weighted average changes
from baseline for the three efﬁcacy measurements were
highly correlated with each other for each treatment group,
with correlations ranging from r¼ 0.766 to 0.902, and for the
combined treatment groups (r¼ 0.778e0.903).Discussion
The purpose of this secondary analysis was two-fold: to
determine the proportions of OMERACTeOARSI
responders from two identical OA trials comparing etori-
coxib, celecoxib, and placebo and to evaluate the ability
of the individual component measurements to predict over-
all response. In general, both etoricoxib and celecoxib had
similar proportions of OMERACTeOARSI responders
(66.2% and 63.5%, respectively), which were signiﬁcantly
greater than that for placebo (43.0%). A recent review arti-
cle noted that although an increasing number of OA trials in-
clude the individual components of the OMERACTeOARSI
responder criteria, few calculated actual responder rates12.
In three trials comparing lumiracoxib, celecoxib, and
placebo that included OMERACTeOARSI responder rates,
results were similar to ours: approximately 60e70%Table I
Sensitivity and specificity of identifying OMERACTeOAR
WOMAC pain WOMAC
Sensitivity (%) Speciﬁcity (%) Sensitivity (%
Etoricoxib 86.9 89.1 86.9
Celecoxib 84.4 83.8 83.0
Placebo 82.9 95.8 80.0
Response was determined by the highest two tertiles of response (i.e.,
tertile 3) were classiﬁed as nonresponders, as detailed in Patients and mresponders in the active treatment groups and 50e60% in
the placebo group13e15. It is worth noting that the seemingly
high placebo responder rates seen in our analysis and the
aforementioned lumiracoxib trials are consistent with the
rates anticipated by the OMERACTeOARSI criteria com-
mittee6,7. This ﬁnding has been seen in other trials, such
as one evaluating chondroitin sulfate16. In the present anal-
ysis, the responder rate in the placebo group may be inﬂu-
enced by the signiﬁcantly greater use of acetaminophen
rescue in the placebo group compared with the active
groups. In addition, discontinuation due to lack of efﬁcacy
was signiﬁcantly more frequent in the placebo group, thus
increasing the likelihood of response for those who
remained in the study.
We also found that a large majority (85.3%) of patients
achieving at least the MCIC from baseline in the three com-
ponent measurements were also classiﬁed as
OMERACTeOARSI responders. Likewise, most (89.1%)
patients with changes from baseline less than the MCIC
were identiﬁed as nonresponders. Thus, each individual
component had high and similar sensitivity and speciﬁcity
for identifying OMERACTeOARSI responders. We also
found that the changes from baseline for each of the mea-
surements were similar and highly correlated with each
other, particularly for the WOMAC pain vs WOMAC physical
function, followed by WOMAC physical function vs PGADS,
and WOMAC pain vs PGADS. This high correlation
between the two WOMAC subscales has been previously
noted in several OA studies (r¼ 0.78e0.90)17e21, as wellI
SI responders by individual domain tertile category
physical function PGADS
) Speciﬁcity (%) Sensitivity (%) Speciﬁcity (%)
85.8 84.0 84.4
83.7 83.9 80.4
91.8 75.4 87.7
tertiles 1/2) for a given measurement; those in the lowest tertile (i.e.,
ethods section.
Table III
Correlation (Pearson’s r) between assessment measures, based
on time-weighted average change from baseline over 12 weeks
Treatment WOMAC pain
vs WOMAC
physical function
WOMAC pain vs
PGADS
WOMAC
physical function
vs PGADS
Etoricoxib
30 mg
(N¼ 471)
0.898 0.766 0.812
Celecoxib
200 mg
(N¼ 482)
0.898 0.762 0.811
Placebo
(N¼ 237)
0.902 0.770 0.804
Combined
(N¼ 1190)
0.903 0.778 0.820
1292 C. O. Bingham et al.: OMERACTeOARSI responder analysisas in a post-knee arthroplasty study22. By comparison, the
reported correlation between WOMAC stiffness and pain
or physical function was considerably lower
(r¼ 0.52e0.76)17,20.
Such strong correlation between the WOMAC pain and
physical function scales suggests the two measures assess
similar constructs. Ryser et al.23 conﬁrmed a redundancy
between the two WOMAC domains, demonstrating that
pain and physical function items (with the exception of
‘‘pain at night while in bed’’) represented a single construct,
while stiffness items represented a separate construct.
This redundancy between the WOMAC pain and physical
function scales may be due to the similarly worded ques-
tions. For example, both scales include items for standing,
walking on a ﬂat surface, going up or down stairs, and lying
in bed. Thus, despite different wording, patients may inter-
pret them similarly, which may account for the high correla-
tion between the two scales17,19,23. For instance, Stratford
and Kennedy24 created two WOMAC physical function
scales: one that contained questions that overlapped with
the pain scale, and one that removed these overlapping
questions, leaving only non-overlapping questions. They
found that using the non-overlapping physical function
subscale and the pain subscale maintained factorial validity
and was able to detect deterioration in functional status,
even when pain improved, whereas the overlapping physi-
cal function subscale and the pain subscale were not able
to detect functional deterioration. Moreover, the correlation
between WOMAC pain and the non-overlapping function
subscale was signiﬁcantly lower than with the overlapping
function subscale, further suggesting that the similar items
in the two scales may be a central issue in the
redundancy24.
However, the WOMAC’s relative insensitivity to distin-
guish pain and physical function may be due to more than
just similar questionnaire items. It has been shown that
patient assessment of physical function is closely tied to,
and dependent on pain levels25, and that subjective assess-
ments of physical function are more likely actually
measuring pain17,19. Indeed, studies have shown that
patient-reported pain and physical function scores can
improve despite worsening performance on objective
physical function tests24,26 with poor correlation reported
between quantitative physical assessments and WOMAC
score27. One study noted that objective assessments
accounted for only 5e14% of the WOMAC score, suggest-
ing that the remaining 85e95% of patient-reported assess-
ments are inﬂuenced by other factors such as fatigue and
depression, as well as other rheumatologic andmusculoskeletal comorbidities27, which has also been
documented by others21,28.
Given these results, it may be prudent to include objec-
tive physical function testing, such as 50-foot walk time or
range of motion, in both research trials and in clinical prac-
tice. Additionally, by combining repetitive questions in the
WOMAC pain and WOMAC physical function scales, it
may be possible to simultaneously streamline patient
assessments while increasing functional validity of the mea-
surements, although one would need to ensure the validity
of a shortened scale24. Another area of future research may
be to consider incorporating a set of standardized physical
function tests into OA responder criteria.
One potential limitation of our present analysis is that it
does not account for differences in response by OA joint
(i.e., knee vs hip), which are known to differ in terms of
responsiveness of the OMERACTeOARSI criteria. In
NSAID studies, the OMERACTeOARSI criteria had 59%
sensitivity to identify responders on active treatment in
knee OA trials and 72% sensitivity in hip OA trials7.
Although the criteria themselves sacriﬁce some exactness
for simplicity, given these expected differences, it would
theoretically be informative to evaluate the differences by
joint, as well as how much each individual response rate
contributed to the overall response rate. However, in the
ANCOVA model for the primary results’ analysis
there was no signiﬁcant effect of study joint on any of the
three co-primary efﬁcacy endpointsdwhich were the
same three endpoints used to calculate response in
the present analyses. As reported in the primary manu-
script, an additional pooled subgroup analysis of the three
co-primary endpoints was consistent with the overall
results, with no signiﬁcant interaction observed between
primary joint and treatment10. Given this similar efﬁcacy
by study joint, it would be unlikely to see a difference in
response rate by study joint. Second, and more importantly,
as noted, the criteria were developed with an inherent
compromise between knee and hip OA. As such, there
are not separate response criteria for knee and hip OA.
Given this, and given the similar efﬁcacy observed in the
main results, we felt that combining both groups was
appropriate.
Our relatively novel approach to identifying responders
(i.e., MCIC) by using the cutpoint value between the top two
tertiles of response and the bottom tertile response11 (i.e.,
the 66.7th percentile) resulted in cutpoints of 11.86 mm
for WOMAC pain, 8.70 mm for WOMAC physical function,
and 12.96 mm for PGADS. These values are generally
similar to those identiﬁed in other OA studies identifying
a change of approximately 10 mm as the minimally percepti-
ble clinical improvement29,30, which were the basis for the
noninferiority bounds in our original trials10, aswell as in other
trials31e33. These values are lower and fundamentally differ-
ent than the minimal clinically important improvement (MCII)
values reported by Tubach and colleagues34, which were
identiﬁed as the 75th percentile of change in patients whose
evaluationof response to treatmentwas ‘‘good’’ (scoreof 4on
a 5-point Likert scale). Because of the different values for
MCII in hip and knee, and because there is a single OMER-
ACTeOARSI calculation for both joints, we could not use
a singlemm-basedcutoff approach. Thus, althoughour tertile
approach avoided this potential pitfall, it likely overestimated
the true number of responders. However, this approach prob-
ably had little effect on the analysis showing similar sensitivity
and speciﬁcity of the component measures to identify re-
sponders, which is supported by the high correlations be-
tween measures reported here and in the literature.
1293Osteoarthritis and Cartilage Vol. 16, No. 11In conclusion, in this secondary analysis of data pooled
from two identical trials, both the etoricoxib and celecoxib
groups had signiﬁcantly more OMERACTeOARSI
responders than the placebo group. Our ﬁnding of high cor-
relation between the individual component measures con-
ﬁrms previous reports, and it is further supported by the
high and similar sensitivity and speciﬁcity of each
component measure to predict overall response.Conﬂict of interest
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